The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Open accessAbstract
Purpose: To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and Methods: The study included 805 patients with PMF age ≤ 70 years recruited from multiple Italian centers and the Mayo Clinic (Rochester, MN), forming two independent learning and validation cohorts. A Cox multivariable model was used to select from among a list of 22 variables those that were predictive of overall survival (OS). Integrated clinical and genetic prognostic models with (MIPSS70-plus) or without (MIPSS70) cytogenetic information were developed. Results: Multivariable analysis identified the following as significant risk factors for OS: hemoglobin < 100 g/L, leukocytes > 25 × 10 9 /L, platelets < 100 × 10 9 /L, circulating blasts ≥ 2%, bone marrow fibrosis grade ≥ 2, constitutional symptoms, absence of CALR type-1 mutation, presence of high–molecular risk mutation (ie, ASXL1, EZH2, SRSF2, IDH1/ 2), and presence of two or more high–molecular risk mutations. By assigning hazard ratio (HR)–weighted points to these variables, three risk categories were delineated for the MIPSS70 model; 5-year OS was 95% in low-risk, 70% in intermediate-risk, and 29% in high-risk categories, corresponding to median OS of 27.7 years (95% CI, 22 to 34 years), 7.1 years (95% CI, 6.2 to 8.1 years), and 2.3 years (95% CI, 1.9 to 2.7 years), respectively. In the MIPSS70-plus model, which included cytogenetic information, four risk categories were delineated, with 5-year OS of 91% in low-risk, 66% in intermediate-risk (HR, 3.2; 95% CI, 1.9 to 5.2), 42% in high-risk (HR, 6.4; 95% CI, 4.1 to 10.0), and 7% very high–risk categories (HR, 17.0; 95% CI, 9.8 to 29.2). Both models remained effective after inclusion of older patients in the analysis. Conclusion: MIPSS70 and MIPSS70-plus provide complementary systems of risk stratification for transplantation-age patients with PMF and integrate prognostically relevant clinical, cytogenetic, and mutation data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationBarbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationTefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 548
Self-citationTargeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 310
Self-citationTefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., Belachew, A. A., Pancrazzi, A., Wassie, E. A., Ketterling, R. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.57 · Cited by 277
Self-citationOne Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al-Kali, A., Ketterling, R. P., Hanson, C. A., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.001 · Cited by 260
Self-citationTargeted deep sequencing in primary myelofibrosis
Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., Gangat, N., & Pardanani, A. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000208 · Cited by 219
Self-citationKröger, N., Giorgino, T., Scott, B. L., Ditschkowski, M., Alchalby, H., Cervantes, F., Vannucchi, A., Cazzola, M., Morra, E., Zabelina, T., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608315 · Cited by 186
Self-citationGuglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Rosti, V., Delaini, F., Maffioli, M., Fanelli, T., Pancrazzi, A., Pietra, D., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761999 · Cited by 186
Self-citationCaramazza, D., Begna, K. H., Gangat, N., Vaidya, R., Siragusa, S., Van Dyke, D. L., Hanson, C., Pardanani, A., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2010.234 · Cited by 178
Self-citationPrimary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24592 · Cited by 163
Self-citationTefferi, A., Lasho, T. L., Tischer, A., Wassie, E. A., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014) · Blood · doi:10.1182/blood-2014-07-588426 · Cited by 161
Self-citationTefferi, A., Lasho, T. L., Finke, C., Belachew, A. A., Wassie, E. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.83 · Cited by 159
Self-citationVannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C. N., Kiladjian, J., Kröger, N. M., Thiele, J., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv203 · Cited by 156
Self-citationImproving Survival Trends in Primary Myelofibrosis: An International Study
Cervantes, F., Dupriez, B., Passamonti, F., Vannucchi, A. M., Morra, E., Reilly, J. T., Demory, J., Rumi, E., Guglielmelli, P., Roncoroni, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0240 · Cited by 130
Self-citationHussein, K., Pardanani, A. D., Dyke, D. L. V., Hanson, C. A., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-08-240135 · Cited by 121
Self-citationGuglielmelli, P., Rotunno, G., Fanelli, T., Pacilli, A., Brogi, G., Calabresi, L., Pancrazzi, A., Vannucchi, A. M., & (AGIMM), O. B. O. T. A. I. P. L. R. S. C. G. I. M. M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.90 · Cited by 88
Self-citationGuglielmelli, P., Rotunno, G., Pacilli, A., Rumi, E., Rosti, V., Delaini, F., Maffioli, M., Fanelli, T., Pancrazzi, A., Pieri, L., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24442 · Cited by 61
Self-citationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
Farhadfar, N., Cerquozzi, S., Patnaik, M. M., & Tefferi, A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.013268 · Cited by 19
Self-citation
Cited by
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationPrimary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 315
Self-citationGIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0107-z · Cited by 306
Self-citationPrimary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Self-citationKramann, R., & Schneider, R. K. (2018) · Blood · doi:10.1182/blood-2018-02-834820 · Cited by 62
Metadata
- Authors
- Guglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., Hanson, C. A., Mannelli, F., Ketterling, R. P., Gangat, N., Rambaldi, A., Passamonti, F., Barosi, G., Barbui, T., Cazzola, M., Vannucchi, A. M., & Tefferi, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-02-01
- Volume
- 36
- Issue
- 4
- Pages
- 310-318
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2775539199
- Cited by
- 552
- References
- 25
- FWCI
- 22.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.